Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

Mengmeng Pan, Di Wang, Jie Xu, Shiwei Jin, Yan Wang, Yi Tao, Yuanfang Liu, Wanyan Ouyang, Xiangqin Weng, Hongmei Yi, Yu Huang, Xinmei Cao, Shuhua Li, Fuyuan Zhang, Weiping Zhang, Chunrui Li, Jian-Qing Mi

Blood blood.2025030559.

https://doi.org/10.1182/blood.2025030559

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 498.

https://doi.org/10.1182/blood-2024-193738

Published: 2024

Journal Articles

Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality

Wei Mu, Ning An, Qiuxia Yu, Guang Hu, Haolong Lin, Chunrui Li

Blood (2024) 144 (Supplement 1): 7174.

https://doi.org/10.1182/blood-2024-210020

Published: 2024

Journal Articles

Predictive Model for Infection Risk in CAR-T Therapy Patients

Ning An, Chunrui Li, Hui Luo, Xinran Wang, Di Wang, Peiling Zhang, Wei Mu, Qiuxia Yu, Yuhan Bao, Yang Gao

Blood (2024) 144 (Supplement 1): 7211.

https://doi.org/10.1182/blood-2024-204477

Published: 2024

Journal Articles

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Chunrui Li, Dehui Zou, Di Wang, Baijun Fang, He Huang, Jianyong Li, Bing Chen, Jing Liu, Xi Zhang, Yujun Dong, Kai Hu, Peng Liu, Jianqing Mi, Kaiyang Ding, Zhenyu Li, Qie Dong, Fuyuan Zhang, Guang Hu, Lu-Gui Qiu

Blood (2024) 144 (Supplement 1): 4761.

https://doi.org/10.1182/blood-2024-204355

Published: 2024

Journal Articles

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Su Shuai, Bin Xu, Chunrui Li, Di Wang, Xiwen Tong, Yi Zhu, Xia Mao, Min Xiao, Donghua Zhang

Blood (2024) 144 (Supplement 1): 7062.

https://doi.org/10.1182/blood-2024-204278

Published: 2024

Journal Articles

Efficacy and Safety of Daratumumab in Light Chain Amyloidosis: A Single-Center Retrospective Study

Xinran Wang, Ning An, Qiuxia Yu, Yuhan Bao, Peiling Zhang, Wei Mu, Chunrui Li, Di Wang, Xiaolu Long

Blood (2024) 144 (Supplement 1): 7833.

https://doi.org/10.1182/blood-2024-204637

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

Heterogeneity and Differentiation Patterns of pDC Cells in pDC-AML: A Novel Perspective from Single-Cell RNA Sequencing

Xingcheng Yang, Juan Peng, Chunrui Li, Yicheng Zhang, Xia Mao, Jue Wang, Jia Wei

Blood (2023) 142 (Supplement 1): 1568.

https://doi.org/10.1182/blood-2023-190826

Published: 2023

Journal Articles

Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes

Xingcheng Yang, Xiaoying Zhang, Juan Peng, Lifang Huang, Shaolong He, Zhiqiong Wang, Liting Chen, Chunrui Li, Ling Ma, Jia Wei

Blood (2023) 142 (Supplement 1): 6448.

https://doi.org/10.1182/blood-2023-190744

Published: 2023

Journal Articles

Patterns of CS1 Expression on Natural Killer Cells and Correlated Factors in Plasma Cell Dyscrasias

Chunrui Li, Di Wang, Chunhui Li, Yanjie Xu, Xia Mao, Yimei Que, Zhe Li, Qiuxia Yu, Ning An, Xiaolu Long

Blood (2023) 142 (Supplement 1): 6686.

https://doi.org/10.1182/blood-2023-184537

Published: 2023

Journal Articles

Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

Chunrui Li, Di Wang, Qiuxia Yu, Zhe Li, Wen Wang, Guang Hu, Wei Mu, Chunhui Li, Ning An, Xiaolu Long, Yuhan Bao

Blood (2023) 142 (Supplement 1): 4854.

https://doi.org/10.1182/blood-2023-181394

Published: 2023

Journal Articles

High Serum ST2 Level Predicts Progression and Poor Prognosis of De novo myelodysplastic Syndrome

Juan Peng, Xingchen Yang, Chunrui Li, Yicheng Zhang, Ling Ma, Jia Wei

Blood (2023) 142 (Supplement 1): 6455.

https://doi.org/10.1182/blood-2023-183057

Published: 2023

Journal Articles

Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study

Chunrui Li, Di Wang, Atsuhiko Hasegawa, Huining Liu, Ning An, Yuhan Bao, Meijuan Huang, Yi Xiao, Donghua Zhang, Miao Zheng, Wei Huang, Lijun Jiang

Blood (2023) 142 (Supplement 1): 4837.

https://doi.org/10.1182/blood-2023-182556

Published: 2023

Journal Articles

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Qiuxia Yu, Daizi Gang, Jue Wang, Liang Huang, Chunrui Li, Yicheng Zhang, Xiaoxi Zhou, Yang Cao

Blood (2023) 142 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2023-180363

Published: 2023

Journal Articles

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Chunrui Li, Lu-Gui Qiu, Di Wang, Yongping Song, He Huang, Jianyong Li, Bing Chen, Jing Liu, Yujun Dong, Kai Hu, Peng Liu, Xi Zhang, Jianqing Mi, Zhenyu Li, Kaiyang Ding, Shiyue Zhang, Guang Hu, Wen Wang

Blood (2023) 142 (Supplement 1): 761.

https://doi.org/10.1182/blood-2023-173427

Published: 2023

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Blood (2022) 140 (Supplement 1): 9289–9291.

https://doi.org/10.1182/blood-2022-157311

Published: 2022

Journal Articles

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Xinyi Lu, Xinyue Chen, Liping Yang, Qiong Yao, Jie Zhao, Shaolong He, Liangming Ma, Chunrui Li, JIA Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 12545–12546.

https://doi.org/10.1182/blood-2022-166285

Published: 2022

Journal Articles

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

Xinyue Chen, Xinyi Lu, Xinwei Wang, Liangming Ma, JIA Wei, Chunrui Li, Junni Wei, Weiwei Tian

Blood (2022) 140 (Supplement 1): 11203–11204.

https://doi.org/10.1182/blood-2022-168896

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Fully Human anti-GPRC5D CAR T-Cell Therapy RD118 Induces Durable Remissions in Relapsed/Refractory Multiple Myeloma

A Phase I Study of a Novel BCMA×CD3 Bispecific Antibody Emb-06 in Relapsed or Refractory Multiple Myeloma

Elucidating Structural Epitope Mapping and Soluble BCMA in the Microenvironment: Impact on Anti-BCMA CAR-T Cell Functionality

Predictive Model for Infection Risk in CAR-T Therapy Patients

Impact of CAR T-Cell Persistence on Clinical Outcomes in Relapsed/Refractory Multiple Myeloma: Insights from the Phase 2 Fumanba-1 Study

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Efficacy and Safety of Daratumumab in Light Chain Amyloidosis: A Single-Center Retrospective Study

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Heterogeneity and Differentiation Patterns of pDC Cells in pDC-AML: A Novel Perspective from Single-Cell RNA Sequencing

Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes

Patterns of CS1 Expression on Natural Killer Cells and Correlated Factors in Plasma Cell Dyscrasias

Long-Term Follow-up of Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

High Serum ST2 Level Predicts Progression and Poor Prognosis of De novo myelodysplastic Syndrome

Ksd-101 in Patients with EBV-Associated Hematologic Neoplasms: Results from an Ongoing Phase I Clinical Study

CD19/CD22 CAR T-Cell Therapy Following Autologous Transplantation Is an Optimizing Strategy in Relapsed/Refractory Central Nervous System Lymphoma

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

ECOG,β2-Microglobulin, Hemoglobin and Lactate Dehydrogenase Can Predict Early Grade ≥ 3 Infection Accurately in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Study from China

Hematological Disorders in Conjunction with Maxillofacial Fungal Cellulitis: A Clinical and Literature Evaluation of 5 Cases

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only